Clinical Trial Results:
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects with Active Lupus Nephritis
Summary
|
|
EudraCT number |
2018-003155-38 |
Trial protocol |
PL |
Global end of trial date |
01 Feb 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
17 Feb 2024
|
First version publication date |
17 Feb 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CNTO1959LUN2001
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT04376827 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Janssen Research & Development, LLC
|
||
Sponsor organisation address |
920, US Highway, South Raritan, NJ, United States, 08869
|
||
Public contact |
Clinical Registry Group, Janssen Research & Development, LLC, clinicaltrialsEU@its.jnj.com
|
||
Scientific contact |
Clinical Registry Group, Janssen Research & Development, LLC, clinicaltrialsEU@its.jnj.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Feb 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Feb 2023
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective of this trial was to evaluate the efficacy of guselkumab in subjects with active Lupus Nephritis (LN)
|
||
Protection of trial subjects |
This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
18 Nov 2020
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 9
|
||
Country: Number of subjects enrolled |
Mexico: 4
|
||
Country: Number of subjects enrolled |
Russian Federation: 3
|
||
Country: Number of subjects enrolled |
Thailand: 1
|
||
Country: Number of subjects enrolled |
Taiwan: 3
|
||
Country: Number of subjects enrolled |
Ukraine: 12
|
||
Country: Number of subjects enrolled |
United States: 1
|
||
Worldwide total number of subjects |
33
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
32
|
||
From 65 to 84 years |
1
|
||
85 years and over |
0
|
|
||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||
Recruitment details |
- | |||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||
Screening details |
Randomization was stratified by geographic region (North America, Latin America, Asia Pacific and Europe) and Urine Protein to Creatinine Ratio (UPCR) level (less than [<] 3 milligrams per milligram [mg/mg] and greater than or equal to [>=] 3 mg/mg). | |||||||||||||||||||||
Period 1
|
||||||||||||||||||||||
Period 1 title |
Double blind Period: Week 0 to Week 52
|
|||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Investigator, Subject | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||
Arm description |
In double-blind period, subjects received placebo matched to guselkumab (400 milligrams [mg]) intravenous (IV) infusion at Weeks 0, 4 and 8 and placebo matched to guselkumab (200 mg) subcutaneous (SC) injection every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Subjects who achieved complete renal response (CRR) at Week 48 and 52, and completed the Week 52 assessments entered the long-term extension (LTE) phase and continued to receive placebo matched to guselkumab SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||||||||
Dosage and administration details |
In double-blind period subjects received placebo matched to guselkumab 200 mg SC q4w from Week 12 through Week 48.
|
|||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Infusion
|
|||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||
Dosage and administration details |
In double-blind period subjects received placebo matched to guselkumab 400 mg IV at Weeks 0, 4 and 8.
|
|||||||||||||||||||||
Arm title
|
Guselkumab | |||||||||||||||||||||
Arm description |
In double-blind period subjects received guselkumab 400 mg IV infusion at Weeks 0, 4 and 8 and guselkumab 200 mg SC injection q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Subjects who achieved CRR at Week 48 and 52, and completed the Week 52 assessments entered LTE phase and continued to receive guselkumab 200 mg SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Guselkumab
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
CNTO1959
|
|||||||||||||||||||||
Pharmaceutical forms |
Infusion
|
|||||||||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||||||||
Dosage and administration details |
In double-blind period subjects received guselkumab 400 mg IV infusion at Weeks 0, 4 and 8.
|
|||||||||||||||||||||
Investigational medicinal product name |
Guselkumab
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
CNTO1959
|
|||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||||||||
Dosage and administration details |
In double-blind period subjects received guselkumab 200 mg SC injection q4w from Week 12 through Week 48.
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Period 2
|
||||||||||||||||||||||
Period 2 title |
LTE Phase:Week 52 to 96(LTE termination)
|
|||||||||||||||||||||
Is this the baseline period? |
No | |||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||
Roles blinded |
Subject, Investigator | |||||||||||||||||||||
Arms
|
||||||||||||||||||||||
Are arms mutually exclusive |
No
|
|||||||||||||||||||||
Arm title
|
Placebo | |||||||||||||||||||||
Arm description |
In double-blind period, subjects received placebo matched to guselkumab (400 milligrams [mg]) intravenous (IV) infusion at Weeks 0, 4 and 8 and placebo matched to guselkumab (200 mg) subcutaneous (SC) injection every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Subjects who achieved complete renal response (CRR) at Week 48 and 52, and completed the Week 52 assessments entered the long-term extension (LTE) phase and continued to receive placebo matched to guselkumab SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
||||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||||||||
Dosage and administration details |
In LTE phase subjects received placebo matched to guselkumab 200 mg SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination).
|
|||||||||||||||||||||
Arm title
|
Guselkumab | |||||||||||||||||||||
Arm description |
In double-blind period subjects received guselkumab 400 mg IV infusion at Weeks 0, 4 and 8 and guselkumab 200 mg SC injection q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Participants who achieved CRR at Week 48 and 52, and completed the Week 52 assessments entered LTE phase and continued to receive guselkumab 200 mg SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | |||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||
Investigational medicinal product name |
Guselkumab
|
|||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||
Other name |
CNTO1959
|
|||||||||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||||||||
Dosage and administration details |
In LTE phase subjects received guselkumab 200 mg SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination) LTE phase.
|
|||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In double-blind period, subjects received placebo matched to guselkumab (400 milligrams [mg]) intravenous (IV) infusion at Weeks 0, 4 and 8 and placebo matched to guselkumab (200 mg) subcutaneous (SC) injection every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Subjects who achieved complete renal response (CRR) at Week 48 and 52, and completed the Week 52 assessments entered the long-term extension (LTE) phase and continued to receive placebo matched to guselkumab SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Guselkumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In double-blind period subjects received guselkumab 400 mg IV infusion at Weeks 0, 4 and 8 and guselkumab 200 mg SC injection q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Subjects who achieved CRR at Week 48 and 52, and completed the Week 52 assessments entered LTE phase and continued to receive guselkumab 200 mg SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Placebo
|
||
Reporting group description |
In double-blind period, subjects received placebo matched to guselkumab (400 milligrams [mg]) intravenous (IV) infusion at Weeks 0, 4 and 8 and placebo matched to guselkumab (200 mg) subcutaneous (SC) injection every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Subjects who achieved complete renal response (CRR) at Week 48 and 52, and completed the Week 52 assessments entered the long-term extension (LTE) phase and continued to receive placebo matched to guselkumab SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | ||
Reporting group title |
Guselkumab
|
||
Reporting group description |
In double-blind period subjects received guselkumab 400 mg IV infusion at Weeks 0, 4 and 8 and guselkumab 200 mg SC injection q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Subjects who achieved CRR at Week 48 and 52, and completed the Week 52 assessments entered LTE phase and continued to receive guselkumab 200 mg SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | ||
Reporting group title |
Placebo
|
||
Reporting group description |
In double-blind period, subjects received placebo matched to guselkumab (400 milligrams [mg]) intravenous (IV) infusion at Weeks 0, 4 and 8 and placebo matched to guselkumab (200 mg) subcutaneous (SC) injection every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Subjects who achieved complete renal response (CRR) at Week 48 and 52, and completed the Week 52 assessments entered the long-term extension (LTE) phase and continued to receive placebo matched to guselkumab SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | ||
Reporting group title |
Guselkumab
|
||
Reporting group description |
In double-blind period subjects received guselkumab 400 mg IV infusion at Weeks 0, 4 and 8 and guselkumab 200 mg SC injection q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Participants who achieved CRR at Week 48 and 52, and completed the Week 52 assessments entered LTE phase and continued to receive guselkumab 200 mg SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | ||
Subject analysis set title |
Guselkumab Vs Placebo
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
In double-blind period, placebo arm subjects received placebo matched to guselkumab (400 mg) IV infusion at Weeks 0, 4 and 8 and placebo matched to guselkumab (200 mg) SC injection q4w from Week 12 through Week 48; Guselkumab arm subjects received guselkumab 400 mg IV infusion at Weeks 0, 4 and 8 and guselkumab 200 mg SC injection q4w from Week 12 through Week 48. All (both arms) subjects received standard-of-care treatment of MMF/MPA and glucocorticoids. Subjects who achieved CRR at Weeks 48 and 52, and completed the Week 52 assessments entered the LTE phase. During the LTE phase, subjects received the same treatment, placebo or guselkumab that was assigned at randomization, SC q4w from Week 52 through Week 84 (that is, up to LTE phase treatment termination).
|
|
|||||||||||||
End point title |
Percentage of Subjects Achieving at Least 50 Percent (%) Decrease From Baseline in Proteinuria at Week 24 [1] | ||||||||||||
End point description |
Percentage of subjects achieving at least 50% decrease in proteinuria from baseline at Week 24 was reported. Proteinuria analysis was based on UPCR and was defined as the presence of an excess of serum proteins in the urine, which may be an early sign of kidney disease. Full analysis set (FAS) included all randomised subjects who received at least 1 dose of study intervention.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics was done, no inferential statistical analysis was performed. |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Time to Achievement of Complete Renal Response | ||||||||
End point description |
Subject was considered as achieved CRR who did not discontinue study intervention for any reason excluding COVID-19 related discontinuations or met medication intercurrent event (exceeded baseline glucocorticoid dose, increase above 10 mg/d prednisone equivalent after Week 12, use of new or increased dose of concomitant medication related to lupus nephritis (LN) or other immunosuppressive agents, within 8 weeks prior to endpoint time point or initiation of prohibited medications at any time prior to endpoint time point. In below data table, measure type "Number"=hazard ratio and unit of measure is ratio for time to CRR.FAS population. For this endpoint, only summary measure (population-level summary) data were analyzed and reported as planned in study statistical analysis plan. Thus, data were presented for single comparative arm (guselkumab vs placebo). ‘N' (number of subjects analysed)=all subjects of both arms with available data for this endpoint.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Up to Week 24
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects who Achieved Complete Renal Response (CRR) at Week 24 | ||||||||||||
End point description |
CRR was defined as UPCR less than (<) 0.5 mg/mg, estimated glomerular filtration rate (eGFR) greater than or equal to (>=) 60 milliliter per minute per 1.73 meter square (mL/min/1.73m^2) or no confirmed decrease >=20% from baseline and prednisone dose less than or equal to (<=) 10 milligrams per day (mg/d). Subject was considered as achieved CRR who did not discontinue study intervention for any reason excluding COVID-19 related discontinuations or met the medication intercurrent event (exceeded baseline glucocorticoid dose, increase above 10 mg/d prednisone equivalent after Week 12, use of new or increased dose of concomitant medication related to LN or other immunosuppressive agents, within 8 weeks prior to the endpoint time point or initiation of prohibited medications at any time prior to the endpoint time point. FAS included all randomised subjects who received at least 1 dose of study intervention.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Time to Treatment Failure (TF) | ||||||||
End point description |
TF:time to first occurrence of TF from baseline. Subject was considered have treatment failure, who did not continue study intervention for any reason excluding COVID-19 related discontinuations or met medication intercurrent event (exceeded baseline glucocorticoid dose, increase above 10 mg/d prednisone equivalent after Week 12, use of new or increased dose of concomitant medication related to LN or other immunosuppressive agents, within 8 weeks prior to endpoint time point or initiation of prohibited medications at any time prior to endpoint time point. In below data table, measure type "Number"= hazard ratio and unit of measure is ratio for time to TF. FAS population. For this endpoint, only summary measure (population-level summary) data were analyzed and reported as planned in study statistical analysis plan. Thus, data were presented for single comparative arm. ‘N' (number of subjects analysed) signifies all subjects of both arms with available data for this endpoint.
|
||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Through Week 52
|
||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||
End point title |
Serum Concentration of Guselkumab [2] | ||||||||||||||||||||||||||||||
End point description |
Serum Concentration of guselkumab were reported. Data for this endpoint was not planned to be collected and analysed for the placebo arm. Pharmacokinetic analysis set included all subjects who received at least 1 administration of guselkumab and had at least one post-dose sample collection. Here (number analysed) signifies number of subjects evaluable at specific timepoints. Since a small number of subjects only entered LTE period than the planned enrollment count, planned serum concentration analysis was not performed for the LTE phase for this endpoint.
|
||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||
End point timeframe |
Predose: Weeks 0,4,8,12,16,20,24, 36; Post-dose: Weeks 0 (1 hour after intravenous administration), Day 2, Week 52 and 60
|
||||||||||||||||||||||||||||||
Notes [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be reported for specified arms only. |
|||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects Achieving a Sustained Reduction in Steroid Dose <=10 mg/d of Prednisone or Equivalent From Week 16 through Week 24 | ||||||||||||
End point description |
Percentage of subjects achieving a sustained reduction in steroid dose less than or equal to (<=) 10 mg/day of prednisone or equivalent from week 16 through Week 24 were reported. FAS included all randomised subjects who received at least 1 dose of study intervention.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
From Week 16 through Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects Achieving at Least 50% Decrease in Proteinuria From Baseline at Week 52 | ||||||||||||
End point description |
Percentage of subjects achieving at least 50% decrease in proteinuria from baseline at Week 52 were reported.FAS included all randomised subjects who received at least 1 dose of study intervention.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects with Urine Protein to Creatinine Ratio (UPCR) < 0.5 mg/mg at Week 24 | ||||||||||||
End point description |
Percentage of subjects with UPCR <0.5 mg/mg at Week 24 were reported. FAS included all randomised subjects who received at least 1 dose of study intervention.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects with UPCR < 0.75 mg/mg at Week 24 | ||||||||||||
End point description |
Percentage of subjects with UPCR less than (<) 0.75 mg/mg at Week 24 were reported. FAS included all randomised subjects who received at least 1 dose of study intervention.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 24
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects with AE Leading to Discontinuation of Study Intervention | |||||||||
End point description |
Number of subjects with AE leading to discontinuation of study intervention were reported. SAS included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE phase than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase subjects and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects with Related AEs | |||||||||
End point description |
Number of subjects with related AEs were reported. An AE was defined as any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product did not necessarily have a causal relationship with the treatment. Therefore, it could be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. Related AE was defined as the AE assessed by the investigator related to study agent. SAS included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE phase than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase subjects and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects with Serious Adverse Events (SAEs) | |||||||||
End point description |
Number of subjects with AEs were reported. A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product, or was medically important. SAS included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE phase than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase participants and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects with Adverse Events (AEs) | |||||||||
End point description |
Number of subjects with AEs were reported. An AE was defined as any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product did not necessarily have a causal relationship with the treatment. Therefore, it could be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. Safety analysis set (SAS) included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE phase than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase subjects and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects with Infections | |||||||||
End point description |
Number of subjects with infections as assessed by the investigator were reported. SAS included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE phase than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase subjects and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects With Serious Infections | |||||||||
End point description |
Number of subjects with serious infections as assessed by the investigator were reported. SAS included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE phase than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase subjects and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects with Infections Requiring Oral or Parenteral Antimicrobial Treatment | |||||||||
End point description |
Number of subjects with infections requiring oral or parenteral antimicrobial treatment were reported. For this endpoint, no data was collected and analysed due to premature termination of the study.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects With AEs Temporally Associated with an Infusion | |||||||||
End point description |
Number of subjects with AEs temporally (a reaction that occurred during of within 1 hour after infusion) associated with an infusion were reported. AE is any untoward medical occurrence in a clinical study subject administered a medicinal (investigational or non-investigational) product does not necessarily have a causal relationship with the treatment. Therefore, it can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to that medicinal product. SAS included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE phase than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase subjects and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of Subjects With AEs with Injection-site Reactions | |||||||||
End point description |
Number of subjects with injection-site reactions as assessed by the investigator were reported. An injection-site reaction is any adverse reaction at a SC study intervention injection-site. SAS included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE phase than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase subjects and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Number of Subjects with Treatment-boosted Anti-drug antibodies (ADA) Response [3] | ||||||||||
End point description |
Treatment-boosted ADA positive subjects: subjects who were positive at baseline and whose titers increased 2-fold at any time after treatment. Titer values were categorised as<=1:10, 10 to 100, 100 to 1000, >1000. Immunogenecity analysis set inlcuded all subjects who received at least 1 administration of guselkumab and had at least one post-dose sample collection. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Data for this endpoint was not planned to be collected and analyzed for the placebo arm.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
From Baseline (Week 0) through Week 24 and Week 60
|
||||||||||
Notes [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: This endpoint was planned to be reported for specified arms only. |
|||||||||||
|
|||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Percentage of Subjects with Abnormal Vital Signs: Systolic and Diastolic Blood Pressure | ||||||||||||||||||||||||
End point description |
Percentage of subjects with abnormal vital signs: Systolic and Diastolic blood pressure were reported. SAS included all subjects who received at least one dose of study intervention. Here "mmHg" refers to millimeter(s) of mercury.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Up to Week 60
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Hematology Parameter: Hematocrit | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: hematocrit was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. 9999=mean and standard deviation (SD) was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Hematology Parameter: Hemoglobin | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: hemoglobin was reported. SAS included all subjects who received at least one dose of study intervention. Here 'n' refers to the number of subjects evaluable at specified timepoints. Here 'N' refers to the number of subjects of both with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint.9999=mean and SD was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter:: Leukocytes | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: leukocytes was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. 9999=mean and SD was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Lymphocytes | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: lymphocytes was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. 9999= mean and SD was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Monocytes | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: monocytes was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. 9999=mean and SD was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Hematology Parameter: Neutrophils, Segmented | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: neutrophils, segmented was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here, 9999=mean and standard deviation (SD) was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Platelets | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: platelets was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and standard deviation (SD) was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Prothrombin International Normalised Ratio | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: prothrombin international normalized ratio was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and standard deviation (SD) was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Prothrombin Time | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: prothrombin time was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and standard deviation (SD) was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Reticulocytes/Erythrocytes | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter:reticulocytes/erythrocytes was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and standard deviation (SD) was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Albumin | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: albumin was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Alanine Aminotransferase | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: alanine aminotransferase was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and standard deviation (SD) was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Alkaline Phosphatase | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: alkaline phosphatase was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Aspartate Aminotransferase | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: aspartate aminotransferase was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Bicarbonate | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: bicarbonate was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean SD was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Bilirubin | ||||||||||||||||||
End point description |
Change from baseline in chemistry parameter: bilirubin was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and SD was not evaluated because only one subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Chloride | ||||||||||||||||||
End point description |
Change from baseline in chemistry parameter: chloride was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameters: Calcium | ||||||||||||||||||
End point description |
Change from baseline in chemistry parameter: calcium was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and SD was not evaluated because only 1 subjects was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameters: Cholesterol | ||||||||||||||||||
End point description |
Change from baseline in chemistry parameter: cholesterol was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Activated Partial Thromboplastin Time | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: activated partial thromboplastin time was reported. SAS population. Here 'n' (number analysed) signifies number of subjects evaluable at specified timepoints. Here 'N' (number of subjects analysed) signifies to number of subjects with available data for this endpoint. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint.9999=signifies that mean and SD was not evaluated because no subject was available for the analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Creatine Kinase | ||||||||||||||||||
End point description |
Change from baseline in chemistry parameter: creatine kinase was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Basophils | ||||||||||||||||||
End point description |
Change from baseline in hematology parameter: basophils was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and SD was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Subjects who Achieved CRR at Week 52 | ||||||||||||
End point description |
CRR was defined as UPCR less than (<) 0.5 mg/mg, eGFR >= 60 mL/min/1.73m^2 or no confirmed decrease >=20% from baseline and prednisone dose <= 10 mg/d. Subject was considered as achieved CRR who did not discontinue study intervention for any reason excluding COVID-19 related discontinuations or met the medication intercurrent event (exceeded baseline glucocorticoid dose, increase above 10 mg/d prednisone equivalent after Week 12, use of new or increased dose of concomitant medication related to LN or other immunosuppressive agents, within 8 weeks prior to the endpoint time point (Week 52) or initiation of prohibited medications at any time prior to the endpoint time point (Week 52). The Full Analyses Set for Week 52 (FASC52) includes all randomized subjects who received at least 1 dose of any study intervention and have the opportunity to complete the Week 52 visit prior to study termination. Here 'N' (number of subjects analyzed) signifies subjects evaluable for this endpoint.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 52
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Creatinine | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: creatinine was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Protein | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: protein was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Phosphate | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: phosphate was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Sodium | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: sodium was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Erythrocytes | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: erythrocytes was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that mean and SD was not evaluated because no subjects were available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratiory Parameters: Potassium | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: potassium was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameters: Urea Nitrogen | ||||||||||||||||||
End point description |
Change from baseline in chemistry parameter: urea nitrogen was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Week 24, and Week 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Glomerular Filtration Rate (GFR) from Creatinine Adjusted for Body Surface Area (BSA) | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: GFR from Creatinine Adjusted for BSA was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Weeks 24 and 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Gamma Glutamyl and Transferase Lactate Dehydrogenase | ||||||||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: gamma glutamyl transferase and lactate dehydrogenase were reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline (Week 0), Weeks 24 and 52
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Glucose and Magnesium | ||||||||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: glucose and magnesium werereported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint. Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||
End point timeframe |
Baseline (Week 0), Weeks 24 and 52
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Change from Baseline in Clinical Laboratory Parameter: Protein/Creatinine | ||||||||||||||||||
End point description |
Change from baseline in clinical labpratory parameter: protein/creatinine was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Weeks 24 and 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Double-blind Period: Change from Baseline in Clinical Laboratory Parameter: Urate | ||||||||||||||||||
End point description |
Change from baseline in clinical laboratory parameter: urate was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint.Here '9999' signifies that SD was not evaluated because only 1 subject was available for analysis.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Weeks 24 and 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Double-blind Period: Change from Baseline in Clinical Laboratory Parameter: Urine Protein | ||||||||||||||||||
End point description |
Change from baseline in clinical labpratory parameter: urine protein was reported. mean and SD was not evaluated because no subject was available for the analysis. Since a small number of subjects only entered the LTE phase than the planned enrollment count, the planned analysis of change from baseline for the safety parameters was not performed for the LTE phase for this endpoint.
|
||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||
End point timeframe |
Baseline (Week 0), Weeks 24 and 52
|
||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects with Maximum US National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Toxicity Grade (Grade 4) in Clinical Laboratory Parameters: Hematology and Chemistry | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Number of subjects with maximum US NCI-CTCAE toxicity grade (Grade 4) in clinical laboratory parameters: hematology and chemistry were reported. Toxicity were graded as Grade 1: Mild, Grade 2: Moderate; Grade 3: Severe. Grade 4: Life-threatening and Grade 5: Death. SAS included all subjects who received at least one dose of study intervention. Since a small number of subjects only entered the LTE period than the planned enrollment count, no separate adverse events analysis was performed for the LTE phase subjects and thus, data of both DB period and LTE phase were presented together for this endpoint under the arms: placebo and guselkumab.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
DB period: From Week 0 up to 12 week safety follow-up (i.e., up to Week 60); LTE phase: From Week 52 up to LTE phase termination (i.e., up to Week 96)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
SAS: all subjects who received at least 1 dose of study drug. Since small number of subjects only entered LTE period than planned enrollment, no separate AEs analysis was performed for LTE phase subjects and thus, data of both DB and LTE period were presented together for AEs (SAEs and non- SAEs) and death data under arms: placebo and guselkumab.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
25.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Guselkumab
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In double-blind period subjects received guselkumab 400 mg IV infusion at Weeks 0, 4 and 8 and guselkumab 200 mg SC injection q4w from Week 12 through Week 48 along with standard-of-care treatment of MMF/MPA and glucocorticoids. Subjects who achieved CRR at Week 48 and 52, and completed the Week 52 assessments entered LTE phase and continued to receive guselkumab 200 mg SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
In double-blind period, subjects received placebo matched to guselkumab (400 milligrams [mg]) intravenous (IV) infusion at Weeks 0, 4 and 8 and placebo matched to guselkumab (200 mg) subcutaneous (SC) injection every 4 weeks (q4w) from Week 12 through Week 48 along with standard-of-care treatment of mycophenolate mofetil (MMF)/mycophenolic acid (MPA) and glucocorticoids. Subjects who achieved complete renal response (CRR) at Week 48 and 52, and completed the Week 52 assessments entered the long-term extension (LTE) phase and continued to receive placebo matched to guselkumab SC injection q4w from Week 52 through Week 84 (that is., up to LTE phase treatment termination) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
07 May 2020 |
It was recognized that the Coronavirus Disease 2019 (COVID-19) pandemic may have an impact on the conduct of this clinical study. In alignment with recent health authority guidance, the Sponsor was providing options for study related subject management in the event of COVID-19 related disruption to the conduct of the study. |
||
20 May 2021 |
Added a LTE to the study for an additional 2 years in order to evaluate long-term efficacy and safety of guselkumab treatment in lupus nephritis. Eligible subjects must have achieved complete renal response (CRR) at Weeks 48 and 52. This amendment also addressesed the use of oral contraceptives (using oral contraceptives with a second method of contraception) with concomitant mycophenolate mofetil (MMF)/mycophenolic acid (MPA) due to changes in their label. |
||
29 Mar 2022 |
Revised the inclusion and exclusion criteria on the use of glucocorticoids and cyclophosphamide to better align with standard of care treatment for lupus nephritis and to enhance enrollment in the study without affecting the Sponsor’s ability to fulfill the objectives of the study. The requirement for collection of plasma biomarkers samples in the long-term extension (LTE) was removed. In addition, Cystatin C testing was now required. Additional changes are also listed in the amendment table below. |
||
24 May 2022 |
Revised the protocol to reflect the sponsor’s decision to stop screening of new subjects and terminate the study early, as a result of enrollment challenges. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Due to enrollment challenges,Sponsor decided to stop screening of new subjects and stop study early. Since small number of subjects entered LTE phase than planned enrollment, some of planned safety analyses were not performed for LTE phase subjects. |